Improved Ex Vivo Hematopoietic Stem Cell Culture System
Hematopoietic stem cell (HSC) transplants are widely used to restore hematopoietic function in patients whose bone marrow or immune system is damaged due to radiation or chemotherapy. The regenerative capability of HSC therapy is currently subject to major limitations as only a few cells can be isolated and these cells show limited ability to duplicate in culture. Michigan State University (MSU) has developed a novel technology that greatly improves the ex vivo expansion of HSCs, potentially enhancing the effectivity of HSC therapy significantly.
Description of Technology
This optimized hematopoietic stem cell (HSC) culture system developed at MSU vastly improves ex vivo expansion of HSCs derived from human cord blood. Culture media is supplemented with UM171 a pyrimido-indole derivative. HSCs are cultured under hypoxic conditions (5% O2) for three days, followed by normoxic conditions (21% O2) for 7 days. Tests with cord blood samples collected from 11 full term newborns showed that these novel culture conditions led to approximately a 25 fold expansion of the collected HSC.
- Easy Implementation: Uses equipment and small molecule which are already readily commercially available.
- Simple: Only requires one small molecule and oxygen manipulation as opposed to complicated sets of factors previously proposed.
- Immune-Rejection Proof: Cells are cultured from a patients’ own HSCs so they will not be rejected from the immune system as donor cells often are
- Cell Culture: Increased ex vivo expansion of limited HSCs pool for transplant back into patient with or without gene editing.
- Research Tool: Increase HSC expansion useful for lab applications.
- Cancer therapy: HSC transplant critical for patients after chemo or radiation therapy to rebuild the immune system.
Licensing Rights Available
Full licensing rights available
Inventors: Dr. Said Omar
Tech ID: TEC2017-0042
For Information, Contact:
Michigan State University